



(11) **EP 2 791 135 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) Int Cl.:  
**C07D 451/02** <sup>(2006.01)</sup> **A61K 31/46** <sup>(2006.01)</sup>  
**A61P 25/00** <sup>(2006.01)</sup>

(48) Corrigendum issued on:  
**18.07.2018 Bulletin 2018/29**

(86) International application number:  
**PCT/US2012/068943**

(45) Date of publication and mention  
of the grant of the patent:  
**06.06.2018 Bulletin 2018/23**

(87) International publication number:  
**WO 2013/090260 (20.06.2013 Gazette 2013/25)**

(21) Application number: **12857224.5**

(22) Date of filing: **11.12.2012**

(54) **ANABASINE DERIVATIVES TARGETING THE NICOTINIC ACETYLCHOLINE RECEPTORS**  
AUF NIKOTINISCHE ACETYLCHOLINREZEPTOREN GERICHTETE ANABASINDERIVATE  
DÉRIVÉS D'ANABASINE CIBLANT LES RÉCEPTEURS NICOTINIQUES DE L'ACÉTYLCHOLINE

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(56) References cited:  
**WO-A1-92/01688 WO-A1-2006/133303**  
**WO-A1-2008/095944 WO-A2-01/23385**

(30) Priority: **12.12.2011 US 201161569539 P**

(43) Date of publication of application:  
**22.10.2014 Bulletin 2014/43**

(73) Proprietor: **KemPharm Consulting Inc.**  
**Gainesville FL 32605 (US)**

(72) Inventors:  
• **KEM, William, Reade**  
**Gainesville, FL 32605-3454 (US)**  
• **SOTI, Ferenc**  
**Gainesville, FL 32601-8521 (US)**  
• **XING, Hong**  
**Gainesville, FL 32605 (US)**

(74) Representative: **Helbig, Christian**  
**Wagner + Helbig**  
**Patentanwälte**  
**Pfarrstrasse 14**  
**80538 München (DE)**

- **SLAVOV S H ET AL: "A computational study of the binding of 3-(arylidene) anabaseines to two major brain nicotinic acetylcholine receptors and to the acetylcholine binding protein", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 45, no. 6, 1 June 2010 (2010-06-01), pages 2433-2446, XP027013913, ISSN: 0223-5234 [retrieved on 2010-02-13]**
- **HASHIMOTO K ET AL: "ALPHA.7 NICOTINIC RECEPTOR AGONISTS AS POTENTIAL THERAPEUTIC DRUGS FOR SCHIZOPHRENIA", CENTRAL NERVOUS SYSTEM AGENTS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS LTD., BUSSUM, NL, vol. 5, no. 3, 1 January 2005 (2005-01-01), pages 171-184, XP009074846, ISSN: 1871-5249**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 2 791 135 B8**

- ANTOINE TALY ET AL: "Discrimination of agonists versus antagonists of nicotinic ligands based on docking onto AChBP structures", JOURNAL OF MOLECULAR GRAPHICS AND MODELLING, ELSEVIER SCIENCE, NEW YORK, NY, US, vol. 30, 22 June 2011 (2011-06-22), pages 100-109, XP028272492, ISSN: 1093-3263, DOI: 10.1016/J.JMGM.2011.06.008 [retrieved on 2011-06-29]
- SVETOSLAV H. SLAVOV ET AL.: 'A computational study of the binding of 3-(aryl idene) anabaseines to two major brain nicotinic acetylcholine receptors and to the acetylcholine binding protein.' EUROPEAN JOURNAL OF MEDICINAL CHEMIST .Y. vol. 45, no. 6, June 2010, pages 2433 - 2446, XP027013913
- KENJI HASHIMOTO ET AL.: 'alpha7 Nicotinic Agonists as Potential Therapeutic Drugs for Schizophrenia.' CURRENT MEDICINAL CHEMISTRY-CENTRAL NERVOUS SYSTEM AGENTS. vol. 5, no. 3, September 2005, pages 171 - 184, XP009074846
- NATALE BELLUARDO ET AL.: 'Central nicotinic receptors, neurotrophic factors and neuroprotection.' BEHAVIOURAL BRAIN RESEARCH. vol. 113, no. 1-2, August 2000, pages 21 - 34, XP055156520
- ALEXANDER HOEPPING ET AL.: 'Novel Conformationally Constrained Tropane Analogues by 6-endo-trig Radical Cyclization and Stille Coupling, Switch of Activity toward the serotonin and/or Norepinephrine Transporter.' JOURNAL OF MEDICINAL CHEMISTRY. vol. 43, no. 10, 18 May 2000, pages 2064 - 2071, XP002169501

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification